Home › Funds › Octagon Capital Advisors LP › BIOA

Octagon Capital Advisors LP position in BIOA

BIOAGE LABS INC · Health Care

Octagon Capital Advisors LP reported holding 1,300,000 shares of BIOA (BIOAGE LABS INC) in its Q3 2026 13F filing — a position valued at US$9.2M, representing 1.23% of its reported portfolio and ranking #17 among its reported holdings. Octagon Capital Advisors LP has disclosed BIOA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)1.30M sh
Reported value held$9.22M
Portfolio Weight1.23%
First reportedQ4 2025
Last changeReduce
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Octagon Capital Advisors LP's BIOA position evolved

Octagon Capital Advisors LP first disclosed a stake in BIOA in Q4 2025 at 1,598,000 shares (US$21.1M). The position peaked in Q2 2026 at 1,748,000 shares, worth US$42.8M. Across 4 filings, Octagon Capital Advisors LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,300,000 shares valued at US$9.2M — a reduction of -448,000 shares quarter over quarter.. Notable position changes include a 26% trim in Q3 2026 (shares fell 26% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 1.60M $21.14M New
Q1 2026 1.75M $30.57M Add
Q2 2026 1.75M $42.84M Hold
Q3 2026 1.30M $9.22M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BIOA and 13F data

BIOA (BIOAGE LABS INC) is a Health Care company. 47 other funds we track also report a position in BIOA — the largest reported positions include a16z Capital Management, L.L.C. (US$22.9M), Sofinnova Investments, Inc. (US$16.3M), Cormorant Asset Management, LP (US$15.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BIOA

All BIOA fund holders →

FAQ

How long has Octagon Capital Advisors LP held BIOA?

Octagon Capital Advisors LP has disclosed BIOA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Octagon Capital Advisors LP's current position in BIOA?

As of Q3 2026, Octagon Capital Advisors LP holds 1.30M shares of BIOA (BIOAGE LABS INC), valued at $9.22M, representing 1.23% of its reported portfolio and ranking #17.

Has Octagon Capital Advisors LP been buying or selling BIOA?

In the latest 13F filing (Q3 2026), Octagon Capital Advisors LP reduced its position in BIOA. The position peaked in Q2 2026 at 1.75M shares.

Which other funds hold BIOA?

Other major institutional holders of BIOA include a16z Capital Management, L.L.C., Sofinnova Investments, Inc., Cormorant Asset Management, LP, among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.